Showing 21-26 of 26 results for "".
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorhttps://modernod.com/news/opthea-appoints-arshad-m-khanani-md-ma-fasrs-as-chief-medical-advisor/2482120/Opthea announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a managing partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinic
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- NovaBay Pharmaceuticals Names Jack McGovern Interim CEOhttps://modernod.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/NovaBay Pharmaceuticals announced that Jack McGovern has been named interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s Chairman and will focus on strat
- Justine Siergeyhttps://modernod.com/profiles/justine-siergey/7Nnpv8/
- Previous
- Next